Coherus Oncology (NASDAQ:CHRS – Get Free Report) and Capricor Therapeutics (NASDAQ:CAPR – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings and institutional ownership.
Analyst Recommendations
This is a summary of recent recommendations and price targets for Coherus Oncology and Capricor Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Coherus Oncology | 1 | 0 | 2 | 0 | 2.33 |
| Capricor Therapeutics | 1 | 6 | 4 | 0 | 2.27 |
Coherus Oncology presently has a consensus target price of $11.00, suggesting a potential upside of 840.17%. Capricor Therapeutics has a consensus target price of $30.25, suggesting a potential upside of 252.98%. Given Coherus Oncology’s stronger consensus rating and higher possible upside, research analysts clearly believe Coherus Oncology is more favorable than Capricor Therapeutics.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Coherus Oncology | $42.17 million | 4.29 | $168.02 million | ($1.03) | -1.14 |
| Capricor Therapeutics | $22.27 million | 22.37 | -$105.04 million | ($2.45) | -3.50 |
Coherus Oncology has higher revenue and earnings than Capricor Therapeutics. Capricor Therapeutics is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Coherus Oncology and Capricor Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Coherus Oncology | -259.41% | -222.75% | -52.11% |
| Capricor Therapeutics | N/A | -56.60% | -43.97% |
Insider & Institutional Ownership
72.8% of Coherus Oncology shares are held by institutional investors. Comparatively, 21.7% of Capricor Therapeutics shares are held by institutional investors. 7.2% of Coherus Oncology shares are held by insiders. Comparatively, 9.2% of Capricor Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Volatility & Risk
Coherus Oncology has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500. Comparatively, Capricor Therapeutics has a beta of 0.72, indicating that its share price is 28% less volatile than the S&P 500.
Summary
Coherus Oncology beats Capricor Therapeutics on 8 of the 14 factors compared between the two stocks.
About Coherus Oncology
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company’s licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
About Capricor Therapeutics
Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.
Receive News & Ratings for Coherus Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
